Table 3 Meta-analysis of the association between XRCC1 Arg194Trp polymorphism and platinum-based chemotherapy in objective response rate, overall survival and median progression-free survival for advanced lung cancer patients.

From: Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy

Genetic comparisons	Study groups	No. of studies^a	Test of association			Model	Test of heterogeneity
Genetic comparisons	Study groups	No. of studies^a	OR^b/HR^c (95% CI)	Z	P-value	Model	χ²	P-value	I²(%)
Objective response rate(OR)
TrpTrp vs. ArgArg	Overall	21	2.07(1.67–2.58)	6.54	<0.001	F	21.87	0.348	8.5
	QS
	High quality	16	2.08(1.66–2.63)	6.13	<0.001	F	20.86	0.141	28.1
	Low quality	5	2.01(1.11–3.66)	2.29	0.022	F	1.00	0.910	0
TrpArg vs. ArgArg	Overall	21	2.11(1.68–2.65)	6.43	<0.001	R	37.21	0.011	46.3
	QS
	High quality	16	1.96(1.51–2.54)	5.06	<0.001	R	30.81	0.009	51.3
	Low quality	5	2.83(1.90–4.22)	5.10	<0.001	R	2.22	0.696	0
TrpTrp+TrpArg vs. ArgArg	Overall	23	2.02(1.66–2.45)	7.04	<0.001	R	37.83	0.019	41.8
	QS
	High quality	18	1.91(1.53–2.38)	5.68	<0.001	R	32.61	0.013	47.9
	Low quality	5	2.63(1.80–3.84)	5.00	<0.001	R	2.11	0.715	0
TrpTrp vs. TrpArg+ArgArg	Overall	21	1.56(1.27–1.91)	4.24	<0.001	F	25.52	0.182	21.6
	QS
	High quality	16	1.62(1.30–2.02)	4.30	<0.001	F	23.68	0.071	36.7
	Low quality	5	1.21(0.69–2.11)	0.67	0.502	F	0.96	0.916	0
Trp vs. Arg	Overall	21	1.69(1.46–1.95)	7.03	<0.001	R	33.41	0.03	40.1
	QS
	High quality	16	1.67(1.39–1.99)	5.61	<0.001	R	31.47	0.008	52.3
	Low quality	5	1.78(1.36–2.33)	4.18	<0.001	R	1.66	0.798	0
Overall survival(HR)
TrpTrp vs. ArgArg	Overall	5	0.84(0.64–1.11)	1.22	0.223	F	5.59	0.232	28.4
TrpArg vs. ArgArg	Overall	5	0.96(0.79–1.16)	0.45	0.653	F	2.05	0.727	0
TrpTrp+TrpArg vs. ArgArg	Overall	3	0.93(0.72–1.21)	0.54	0.590	F	0.46	0.795	0
Median progression-free survival(HR)
TrpTrp vs. ArgArg	Overall	3	1.01(0.69–1.48)	0.07	0.948	F	2.17	0.338	7.8
TrpArg vs. ArgArg	Overall	3	1.06(0.82–1.36)	0.44	0.662	F	0.49	0.782	0
TrpTrp+TrpArg vs. ArgArg	Overall	2	1.05(0.79–1.38)	0.31	0.753	F	0.89	0.346	0

Note: OR, odds ratio; HR: hazard ratio; CI, confidence interval; vs., versus; QS: quality score; TrpTrp vs. ArgArg: Homozygote comparison; TrpArg vs. ArgArg: Heterozygote comparison; TrpTrp+TrpArg vs. ArgArg: Dominant model; TrpTrp vs. TrpArg+ArgArg: Recessive model; Trp vs. Arg: Allele contrast; F, fixed effect model; R, random effect model; Random effect model was chosen when P-value < 0.10 and/or I² > 50% for heterogeneity test; otherwise fixed effect model was used.
^aThe detailed references are given in Table 1.
^bThe OR for objective response rate.
^cThe HR for overall survival and median progression-free survival.

Back to article page

Table 3 Meta-analysis of the association between XRCC1 Arg194Trp polymorphism and platinum-based chemotherapy in objective response rate, overall survival and median progression-free survival for advanced lung cancer patients.

Search

Quick links